uniQure (NASDAQ:QURE - Get Free Report) had its price target reduced by equities researchers at HC Wainwright from $80.00 to $65.00 in a report issued on Wednesday, Benzinga reports. The firm presently has a "buy" rating on the biotechnology company's stock. HC Wainwright's target price would indicate a potential upside of 212.80% from the stock's current price.
QURE has been the topic of several other reports. The Goldman Sachs Group dropped their target price on uniQure from $46.00 to $31.00 and set a "neutral" rating on the stock in a report on Wednesday, September 30th. Wells Fargo & Company reissued an "overweight" rating and issued a $75.00 price target on shares of uniQure in a report on Tuesday, September 29th. Wolfe Research upgraded uniQure from a "peer perform" rating to an "outperform" rating and set a $65.00 price objective on the stock in a research report on Wednesday, July 29th. William Blair raised shares of uniQure to a "strong-buy" rating in a research note on Wednesday, September 23rd. Finally, Wall Street Zen raised shares of uniQure from a "sell" rating to a "hold" rating in a report on Saturday, November 7th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, uniQure has a consensus rating of "Moderate Buy" and an average target price of $55.58.
View Our Latest Stock Analysis on QURE
uniQure Price Performance
NASDAQ:QURE opened at $20.78 on Wednesday. The firm's fifty day moving average is $28.55 and its two-hundred day moving average is $29.66. The company has a quick ratio of 11.52, a current ratio of 11.52 and a debt-to-equity ratio of 0.17. uniQure has a one year low of $8.73 and a one year high of $51.72.
uniQure (NASDAQ:QURE - Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The biotechnology company reported ($0.88) earnings per share for the quarter, beating analysts' consensus estimates of ($0.92) by $0.04. The business had revenue of $5.20 million during the quarter, compared to analyst estimates of $6.17 million. uniQure had a negative return on equity of 96.34% and a negative net margin of 1,154.84%. As a group, equities analysts forecast that uniQure will post -3.83 EPS for the current fiscal year.
Hedge Funds Weigh In On uniQure
Institutional investors and hedge funds have recently modified their holdings of the business. Orbimed Advisors LLC lifted its holdings in uniQure by 189.7% during the first quarter. Orbimed Advisors LLC now owns 2,136,149 shares of the biotechnology company's stock valued at $34,926,000 after purchasing an additional 1,398,749 shares in the last quarter. Two Seas Capital LP purchased a new stake in shares of uniQure during the third quarter worth about $31,988,000. Assenagon Asset Management S.A. increased its stake in shares of uniQure by 249.9% during the second quarter. Assenagon Asset Management S.A. now owns 513,530 shares of the biotechnology company's stock worth $23,653,000 after purchasing an additional 366,781 shares in the last quarter. Siren L.L.C. purchased a new stake in shares of uniQure during the first quarter worth about $16,350,000. Finally, Marshall Wace LLP raised its position in shares of uniQure by 89.1% during the 3rd quarter. Marshall Wace LLP now owns 576,162 shares of the biotechnology company's stock worth $13,920,000 after purchasing an additional 271,460 shares during the last quarter. Hedge funds and other institutional investors own 78.83% of the company's stock.
uniQure Company Profile
(
Get Free Report)
uniQure N.V. is a biotechnology company that develops gene therapies for serious genetic and other diseases. The company uses adeno-associated virus (AAV) vectors to deliver genetic material to patients' cells, with research and development operations in the United States and the Netherlands. Its programs have targeted conditions including Huntington's disease, epilepsy and hemophilia B. uniQure developed the gene therapy now known as Hemgenix for hemophilia B; it is commercialized by CSL Behring under a partnership.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider uniQure, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and uniQure wasn't on the list.
While uniQure currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.